Page last updated: 2024-08-26

sr141716 and Smoking Cessation

sr141716 has been researched along with Smoking Cessation in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	33 (84.62)	29.6817
2010's	6 (15.38)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anthenelli, RM; Aubin, HJ; Cinciripini, PM; Dale, LC; Karam-Hage, M; Niaura, R; Robinson, JD	1
Rapezzi, C; Volpe, M	1
Carrozzi, L; Pistelli, F; Viegi, G	1
Chang, Y; Dale, LC; Gonzales, D; Lawrence, D; Rigotti, NA	1
Stapleton, JA	1
Aveyard, P; Hajek, P; Inglis, J; Parsons, AC; Shraim, M	1
Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T	1
Crippa, JA; Moreira, FA	1
Bhat, A; Crain, D	1
Agboola, S; Coleman, T; Leonardi Bee, J; McNeill, A	1
Agboola, S; Coleman, T; Leonardi-Bee, J; McEwen, A; McNeill, A; Taylor, M	1
Cahill, K; Ussher, MH	1
Noble, EP; Oskooilar, N; Wilcox, CS	1
Allison, DB; Fernandez, JR	1
Einecke, D	1
Böcking, W; Bramlage, P; Kirch, W; Mueller, EA	1
Kvasnicka, T	1
Camarelles Guillem, F	1
Cox, SL	1
Borel, ML; Guevel-Jointret, AL; Mansourati, J; Munier, S	1
Shah, S; Tear, S	1
Marx, J	1
Tonstad, S	1
Cannon, CP; Gelfand, EV	2
Corelli, RL; Hudmon, KS	1
Halford, JC; Harrold, JA; Kirkham, TC; Tucci, SA	1
Wierzbicki, AS	1
Bifulco, M; Gazzerro, P; Grimaldi, C; Pisanti, S; Santoro, A	1
Frishman, WH	1
Pipe, AL; Quinlan, B; Reid, RD; Riley, DL	1
Cahill, K; Ussher, M	2
Anthenelli, RM	1
Foulds, J; Steinberg, MB	1
Cahill, K; Lancaster, T; Stead, L	1
Wonnacott, S	1
Aubin, HJ; Forget, B; Goldberg, SR; Le Foll, B	1

Reviews

25 review(s) available for sr141716 and Smoking Cessation

Article	Year
Pharmacotherapy for smoking cessation. Therapeutic advances in respiratory disease, 2008, Volume: 2, Issue:5 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Benzazepines; Bupropion; Humans; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Randomized Controlled Trials as Topic; Rimonabant; Smoking Cessation; Treatment Outcome; Varenicline	2008
Interventions for preventing weight gain after smoking cessation. The Cochrane database of systematic reviews, 2009, Jan-21, Issue:1 Topics: Antidepressive Agents; Benzazepines; Exercise; Female; Humans; Male; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Varenicline; Weight Gain	2009
The psychiatric side-effects of rimonabant. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2009, Volume: 31, Issue:2 Topics: Anxiety Disorders; Appetite Depressants; Cannabinoid Receptor Modulators; Depressive Disorder; Humans; Metabolic Diseases; Obesity; Piperidines; Placebo Effect; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation	2009
A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction (Abingdon, England), 2010, Volume: 105, Issue:8 Topics: Bupropion; Counseling; Dopamine Uptake Inhibitors; Female; Humans; Nicotinic Agonists; Patient Education as Topic; Piperidines; Postnatal Care; Pregnancy; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Secondary Prevention; Self Care; Smoking Cessation; Smoking Prevention; Treatment Outcome	2010
Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis. Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:49 Topics: Benzazepines; Cost-Benefit Analysis; Evidence-Based Medicine; Health Promotion; Humans; Nicotinic Agonists; Piperidines; Public Health; Pyrazoles; Qualitative Research; Quinoxalines; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Social Marketing; State Medicine; Treatment Failure; United Kingdom; Varenicline	2010
Cannabinoid type 1 receptor antagonists for smoking cessation. The Cochrane database of systematic reviews, 2011, Mar-16, Issue:3 Topics: Amides; Body Weight; Humans; Piperidines; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention	2011
Rimonabant Sanofi-Synthélabo. Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:4 Topics: Animals; Anti-Obesity Agents; Antipsychotic Agents; Appetite Depressants; Clinical Trials as Topic; Humans; Obesity; Piperidines; Potassium Channel Blockers; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Structure-Activity Relationship	2004
[Innovation instead of imitation -- news in drug therapy]. Deutsche medizinische Wochenschrift (1946), 2005, Apr-01, Volume: 130, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Anticoagulants; Antineoplastic Agents; Azetidines; Body Weight; Cannabinoid Receptor Antagonists; Cetuximab; Drug Therapy; Ezetimibe; Fondaparinux; Humans; Hypoglycemic Agents; Insulin; Osteoporosis, Postmenopausal; Piperidines; Polysaccharides; Pyrazoles; Rimonabant; Smoking Cessation; Teriparatide; Thromboembolism	2005
[Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation]. Casopis lekaru ceskych, 2005, Volume: 144, Issue:2 Topics: Arachidonic Acids; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Metabolic Syndrome; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rimonabant; Smoking; Smoking Cessation; Weight Loss	2005
Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:8 Topics: Animals; Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Smoking Cessation	2005
[Medications in smoking cessation]. Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18 Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Cannabinoid Receptor Antagonists; Cannabinoids; Central Nervous System Stimulants; Chewing Gum; Child; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Piperidines; Polymethacrylic Acids; Polyvinyls; Pyrazoles; Rimonabant; Smoking Cessation; Surveys and Questionnaires; Time Factors; Tobacco Use Cessation Devices	2005
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:2 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain	2006
Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:3 Topics: Animals; Disease Management; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Smoking; Smoking Cessation	2006
Pharmacologic interventions for smoking cessation. Critical care nursing clinics of North America, 2006, Volume: 18, Issue:1 Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Critical Care; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Nurse's Role; Patient Education as Topic; Patient Selection; Phytotherapy; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Smoking Prevention; United States; United States Food and Drug Administration; Varenicline	2006
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. Journal of the American College of Cardiology, 2006, May-16, Volume: 47, Issue:10 Topics: Animals; Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Lipid Metabolism; Marijuana Abuse; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation	2006
Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Current medicinal chemistry, 2006, Volume: 13, Issue:22 Topics: Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Smoking Cessation; Substance-Related Disorders	2006
Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International journal of clinical practice, 2006, Volume: 60, Issue:12 Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Factors; Smoking Cessation	2006
Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Molecular pharmacology, 2007, Volume: 71, Issue:6 Topics: Anti-Obesity Agents; Antineoplastic Agents; Body Weight; Humans; Neurodegenerative Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Substance-Related Disorders	2007
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. Preventive cardiology, 2007,Spring, Volume: 10, Issue:2 Suppl 1 Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Coronary Artery Disease; Humans; Monoamine Oxidase Inhibitors; Nicotine; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Selective Serotonin Reuptake Inhibitors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline	2007
Smoking cessation: lessons learned from clinical trial evidence. Current opinion in cardiology, 2007, Volume: 22, Issue:4 Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dopamine Uptake Inhibitors; Humans; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Varenicline	2007
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3 Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Smoking Prevention; Suicide	2007
Rimonabant for treating tobacco dependence. Vascular health and risk management, 2007, Volume: 3, Issue:3 Topics: Animals; Cannabinoid Receptor Modulators; Humans; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Smoking; Smoking Cessation; Tobacco Use Disorder	2007
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. The Cochrane database of systematic reviews, 2007, Oct-17, Issue:4 Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Suicide	2007
An update on therapeutics for tobacco dependence. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:1 Topics: Alkaloids; Anti-Anxiety Agents; Azocines; Benzazepines; Bupropion; Clinical Trials as Topic; Databases, Bibliographic; Humans; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinolizines; Quinoxalines; Review Literature as Topic; Rimonabant; Smoking; Smoking Cessation; Varenicline	2008
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addiction biology, 2008, Volume: 13, Issue:2 Topics: Animals; Brain; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Drug Evaluation, Preclinical; Emotions; Humans; Motivation; Nicotine; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Tobacco Use Disorder	2008

Trials

3 trial(s) available for sr141716 and Smoking Cessation

Article	Year
Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation. Addiction biology, 2018, Volume: 23, Issue:1 Topics: Adult; Anorexia; Anxiety; Cannabinoid Receptor Antagonists; Cigarette Smoking; Diarrhea; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Rimonabant; Smoking Cessation; Vomiting	2018
A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction (Abingdon, England), 2009, Volume: 104, Issue:2 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Counseling; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Odds Ratio; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; Weight Gain; Young Adult	2009
ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2011, Volume: 59, Issue:8 Topics: Carbon Monoxide; Genetic Loci; Humans; Pilot Projects; Piperidines; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Pyrazoles; Receptors, Dopamine D2; Rimonabant; Smoking Cessation; Treatment Outcome	2011

Other Studies

11 other study(ies) available for sr141716 and Smoking Cessation

Article	Year
[Residual risk in cardiovascular prevention]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Atherosclerosis; Blood Pressure; Body Weight; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Humans; Hypolipidemic Agents; Kaplan-Meier Estimate; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Smoking Cessation; Thiazolidines; Time Factors	2008
Trial comes too late as psychiatric side effects end hope for rimonabant. Addiction (Abingdon, England), 2009, Volume: 104, Issue:2 Topics: Administration, Cutaneous; Attitude; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation	2009
[Current and future medical drugs for smoking cessation]. Laryngo- rhino- otologie, 2009, Volume: 88, Issue:6 Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline	2009
Current treatment options in smoking cessation. Hospital practice (1995), 2010, Volume: 38, Issue:1 Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Patient Selection; Piperidines; Practice Guidelines as Topic; Pyrazoles; Quinoxalines; Rimonabant; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; United States; Vaccines; Varenicline	2010
[A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Cannabinoid Receptor Antagonists; Coronary Artery Disease; Dose-Response Relationship, Drug; Humans; Lipids; Metabolic Syndrome; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Smoking Cessation; United States; Weight Loss	2004
[Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction]. MMW Fortschritte der Medizin, 2004, Mar-04, Volume: 146, Issue:10 Topics: Appetite; Body Weight; Brain; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome	2004
[Medication for ending tobacco dependency. Current state]. Atencion primaria, 2005, Jun-30, Volume: 36, Issue:2 Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Humans; Nicotine; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Smoking Cessation; Time Factors; Tobacco Use Disorder; Varenicline	2005
Tackling obesity and nicotine dependence. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:12 Topics: Animals; Humans; Immunotherapy; Indoles; Obesity; Piperidines; Pyrazoles; Rimonabant; Serotonin Antagonists; Smoking Cessation; Tobacco Use Disorder	2005
Drug development. Drugs inspired by a drug. Science (New York, N.Y.), 2006, Jan-20, Volume: 311, Issue:5759 Topics: Animals; Anti-Obesity Agents; Anxiety; Arachidonic Acids; Blood Pressure; Brain; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Endocannabinoids; Humans; Inflammation; Neurons; Obesity; Osteoporosis; Pain; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Smoking Cessation	2006
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence. Nature clinical practice. Cardiovascular medicine, 2007, Volume: 4, Issue:9 Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline	2007
Smoking cessation 2008. IDrugs : the investigational drugs journal, 2008, Volume: 11, Issue:4 Topics: Benzazepines; Cannabinoid Receptor Antagonists; Drug Prescriptions; Humans; Marketing of Health Services; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Vaccines; Varenicline	2008